Crofelemer Shows Early Promise in SBS-IF: Ostomy Output Down, Urinary Output Up 88%
JAGX sits 72% above its 52-week low of $2.35 on light trading volume (0.2× avg).
Summary
Jaguar Health presented positive preliminary results from an open-label pilot study of crofelemer in adult short bowel syndrome with intestinal failure (SBS-IF) at ACG 2026. In four completed subjects, two showed a 5% average reduction in ostomy volume, three had increased ostomy output after stopping treatment (avg 23%), one reduced parenteral support volume by 9%, and three improved urinary output by an average 88% sustained post-treatment. No significant adverse events were reported. This is the first disclosure of these specific efficacy signals, supporting the company's rare disease intestinal failure program. The data follow prior pediatric results presented at ESPGHAN in June 2026 and precede a planned Phase 2 trial readout in H2 2027 and an NDA filing for MVID in mid-2027. Given the company's going concern status and heavy dilution overhang, positive clinical data is a meaningful but early-stage development.
At the time of this announcement, JAGX was trading at $4.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $2.35 to $1,260.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.